Uterine leiomyosarcoma diagnosed during treatment with agonist of luteinizing hormone-releasing hormone for presumed uterine fibroid.
Medical treatment with an LH-RH agonist may be used in selected cases of uterine fibroids. Although rare, rapid increase in uterine or fibroid volume may suggest an underlying leiomyosarcoma that would require prompt surgical intervention. Close monitoring of the response to treatment with an LH-RH agonist is essential.
Loong
E P
EP
Department of Obstetrics and Gynaecology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin.
Wong
F W
FW
D000280:Administration, Inhalation; D000328:Adult; D002064:Buserelin / Q000008:administration & dosage / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D006801:Humans; D007889:Leiomyoma / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D007890:Leiomyosarcoma / Q000175:diagnosis* / Q000473:pathology; D008297:Male; D014594:Uterine Neoplasms / Q000175:diagnosis* / Q000473:pathology
D007987:Gonadotropin-Releasing Hormone; D002064:Buserelin